

Special Issue

Recent Advances in Melatonin for Cancer Therapy

Message from the Guest Editor

Melatonin (N-acetyl-5-methoxytryptamine) is a hormone synthesized and secreted mainly by the pineal gland in the dark. In the last 20 years, multiple reports (clinical trials and in vivo and in vitro studies) have documented that the pineal hormone has many potential benefits when it is included in protocols designed to treat tumors because it modulates tumor gene expression impairing cell growth and inhibiting angiogenesis and metastasis. As melatonin has no toxicity, it deserves to be considered as an agent for use as a co-adjuvant in cancer prevention and treatment. This Special Issue aims to bring together current knowledge about melatonin targeting, delivery, and dosage form design (as controlled-release systems), and the newest findings concerning melatonin pharmacokinetics (absorption, distribution, metabolism, and excretion) and pharmacodynamics (interactions between melatonin and its different receptors, such as MT-1, MT-2, calmodulin, or nuclear receptors).

Guest Editor

Dr. Javier Menéndez-Menéndez

Department of Physiology and Pharmacology, School of Medicine,
University of Cantabria, Santander, Spain

Deadline for manuscript submissions

closed (20 January 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/133545

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, New Jersey 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).